Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.
Larson
Jill S Melicher
JS
Department of Ophthalmology, University of Minnesota, Minneapolis, MN 55455, USA. melic014@umn.edu
Bergstrom
Lance K
LK
Cameron
J Douglas
JD
Erickson
Lori A
LA
Grimm
Terrence E
TE
D000368:Aged; D001549:Benzamides; D004487:Edema / Q000139:chemically induced*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D009916:Orbital Diseases / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl